Abstract
Pancreatic adenocarcinoma is the fifth most common cause of cancer-related mortality in the world. The nucleoside analogue gemcitabine is the established standard therapy for advanced disease. Rare cases of gemcitabine-associated systemic capillary leak syndrome have been reported. Here, we present two cases of capillary-leak syndrome in patients with pancreatic cancer treated with gemcitabine.
Publication types
-
Case Reports
-
English Abstract
MeSH terms
-
Adenocarcinoma / drug therapy*
-
Adenocarcinoma / secondary
-
Aged
-
Antimetabolites, Antineoplastic / adverse effects*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Capillary Leak Syndrome / chemically induced*
-
Deoxycytidine / adverse effects
-
Deoxycytidine / analogs & derivatives*
-
Edema / chemically induced*
-
Fatal Outcome
-
Female
-
Gemcitabine
-
Humans
-
Liver Neoplasms / secondary
-
Male
-
Middle Aged
-
Neoadjuvant Therapy
-
Pancreatic Neoplasms / drug therapy*
-
Peritoneal Neoplasms / secondary
-
Radiotherapy, Adjuvant
-
Ribonucleotide Reductases / antagonists & inhibitors*
Substances
-
Antimetabolites, Antineoplastic
-
Deoxycytidine
-
Ribonucleotide Reductases
-
Gemcitabine